Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
SAVAAUSTIN, Texas, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced management’s participation in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8 – 10, 2025 in New York City.
Cassava Reports Q2 2025 Financials Results and Provides Business Update
SAVAAUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the second quarter ended June 30, 2025 and provided a business update.
Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer
SAVAAUSTIN, Texas, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced the appointment of Dr. Joseph Hulihan as Chief Medical Officer (CMO). Dr. Hulihan will devote approximately half of his professional time to Cassava, advising on the clinical development of simufilam, Cassava’s investigational candidate for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy.
Cassava Sciences Q1 EPS $(0.48) Down From $(0.43) YoY
SAVAHC Wainwright & Co. Reiterates Neutral on Cassava Sciences, Maintains $2 Price Target
SAVACassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop
SAVACassava Sciences is ending simufilam development for Alzheimer's after Phase 3 trials failed. The company is shifting focus to potential seizure treatments.
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Study Data
SAVACassava Sciences Q4 2024 GAAP EPS $(0.57) Beats $(0.66) Estimate, $128.6M In Cash And Cash Equivalents
SAVACassava Sciences Entered Into An Agreement With Yale University For A License To Intellectual Property Rights, Including An Exclusive License To An Issued US Method Of Treatment Patent For Simufilam As A Potential Treatment For Seizures Related To Rare Ne
SAVACORRECTION: Cassava Sciences Appoints Freda Nassif As CCO
SAVACassava Sciences Appoints Freda Nassif As COO
SAVACassava Sciences' Simufilam 100 Mg For Mild-To-Moderate Alzheimer's Disease (RETHINK-ALZ) Posted On ClinicalTrials Website On November 15, 2024
SAVAUnpacking the Latest Options Trading Trends in Cassava Sciences
SAVAPeering Into Cassava Sciences's Recent Short Interest
SAVAHC Wainwright & Co. Maintains Buy on Cassava Sciences, Raises Price Target to $131
SAVACassava Sciences Option Alert: Fri $31 Calls Sweep (5) near the Ask: 1000 @ $0.43 vs 718 OI; Ref=$30.75
SAVAWhat Are Whales Doing With Cassava Sciences
SAVASomeone with a lot of money to spend has taken a bullish stance on Cassava Sciences (NASDAQ:SAVA).
And retail traders should know.
We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
Here's How Much You Would Have Made Owning Cassava Sciences Stock In The Last 5 Years
SAVACassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 5 years by 25.46% on an annualized basis producing an average annual return of 37.25%. Currently, Cassava Sciences has a market capitalization of $844.87 million.
